Heron Therapeutics posted Q2 2025 net revenue of $37.2 million, driven by growth in its Acute Care franchise. Despite strong product demand, the company reported a net loss of $2.38 million with an EPS of -$0.02. Cash, cash equivalents, and short-term investments stood at $40.6 million at quarter end.

Heron Therapeutics, Inc. reported a net income of $2.635 million for the three months ended March 31, 2025, a substantial improvement compared to a net loss of $3.160 million in the same period last year. This positive shift was primarily driven by an 89.4% increase in acute care net product sales, particularly ZYNRELEF and APONVIE, and a decrease in research and development and general and administrative expenses.

Heron Therapeutics reported a successful Q4 2024, achieving GAAP net income of $3.6 million. Full-year 2024 net revenue reached $144.2 million, a 14% increase year-over-year. The company is focused on expanding ZYNRELEF's market reach and indications, supported by strategic partnerships and regulatory approvals.

Heron Therapeutics announced its Q3 2024 financial results, reporting positive Adjusted EBITDA and continued revenue growth. The company is narrowing its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA. Key developments include the approval and upcoming launch of the ZYNRELEF VAN and the inclusion of ZYNRELEF in the CMS Final Rule Non-Opioid Policy for Pain Relief.

Heron Therapeutics reported a net product sales increase in the second quarter of 2024, driven by growth in both acute care and oncology care franchises. The company is also improving financial efficiency by growing revenues, improving margins, and reducing expenses.

Heron Therapeutics reported a net product sales increase to $34.7 million, up from $29.6 million in the same period last year. The company's gross margin significantly improved to 76% from 43% year-over-year, and the net loss per share decreased from $(0.27) to $(0.02).

Heron Therapeutics reported increased sales in both acute care and oncology care franchises for Q4 2023. ZYNRELEF achieved a quarterly record of $5.6 million in net product sales. The company ended the year with $80.4 million in cash and cash equivalents.

Heron Therapeutics announced its near completion of the corporate restructuring plan and provided an optimistic outlook for profitability. The company updated its full-year 2023 net product sales guidance for the oncology care franchise to a range of $104 million to $106 million and anticipates full-year 2023 net product sales to be in the range of $123 million to $125 million.

Heron Therapeutics announced its Q2 2023 financial results, highlighting a focus on resizing the business and a cost reduction program expected to save approximately $75 million through 2025. The company also completed a $30 million equity financing and closed a $50 million working capital facility to bolster its balance sheet.

Heron Therapeutics reported a 26% increase in net product sales for Q1 2023, reaching $29.6 million, driven primarily by the oncology care franchise. The company is focused on enhancing the value of ZYNRELEF, addressing application issues, and reducing cash burn through improved operational efficiency.

Heron Therapeutics reported a net product sales increase for the fourth quarter of 2022, driven by growth in both its acute care and oncology care franchises. The company launched APONVIE and saw continued growth in ZYNRELEF sales. A significant reduction in cost of goods for CINVANTI was achieved.

Heron Therapeutics announced its Q3 2022 financial results, with net product sales of $26.6 million, an increase compared to $23.2 million for the same period in 2021. The company's net loss was $41.9 million, or $0.38 per share. The FDA approved APONVIE, and the company plans a U.S. launch in Q1 2023. ZYNRELEF unit demand grew 18% over the prior quarter, and oncology care franchise net product sales grew 13% over the prior year.

Heron Therapeutics reported a net product sales increase to $27.6 million for Q2 2022, driven by a 140% increase in ZYNRELEF sales compared to Q1 and a 12% growth in oncology care franchise sales. The company is implementing a restructuring and cost reduction plan expected to reduce annual operating expenses by over $50 million in 2023. With recent private placement proceeds, Heron's pro-forma cash at the end of Q2 was $158.7 million, projected to provide a cash runway through 2024.

Heron Therapeutics reported a net loss of $63.9 million, or $0.63 per share, for the three months ended March 31, 2022. ZYNRELEF unit demand increased 68% compared to the prior quarter, and Oncology Care Franchise net revenue increased by 13% over the prior quarter.

Heron Therapeutics reported net product sales of $20.7 million for the three months ended December 31, 2021. The company's net loss for the same period was $54.6 million, or $0.54 per share.

Heron Therapeutics announced its Q3 2021 financial results, which included the commercial launch of ZYNRELEF with $2.1 million in net product sales, stabilization of oncology care franchise net product sales at $21.1 million, and a net loss of $52.4 million. The company is focusing on expanding the ZYNRELEF label and expects moderate growth in oncology care sales in 2022.

Heron Therapeutics reported net product sales of $22.4 million for the three months ended June 30, 2021, compared to $22.7 million for the same period in 2020. The net loss for the quarter was $61.0 million, or $0.62 per share, compared to $55.2 million, or $0.61 per share, for the same period in 2020. ZYNRELEF was commercially launched on July 1, 2021, and the oncology care franchise saw a 12% increase in net product sales compared to the prior quarter.

Heron Therapeutics reported a net loss of $52.6 million for the first quarter of 2021. Net product sales were $20.0 million, a decrease from $25.4 million in the same period of 2020. The company is awaiting the FDA's decision on its New Drug Application for HTX-011.

Heron Therapeutics reported net product sales of $20.6 million for the quarter ended December 31, 2020, and a net loss of $62.3 million, or $0.68 per share. The company ended the year with $208.5 million in cash, cash equivalents, and short-term investments. They anticipate a transformational year in 2021 with growth in CINV products and the potential approval and launch of HTX-011.

Heron Therapeutics announced financial results for Q3 2020, with a net loss of $58.2 million and CINV franchise net product sales of $20.0 million. The company is focused on resubmitting the New Drug Application for HTX-011 in the U.S. and saw the authorization of ZYNRELEF in the EU.

Heron Therapeutics reported net product sales of $22.7 million for the three months ended June 30, 2020, compared to $36.7 million for the same period in 2019. The net loss for the three months ended June 30, 2020 was $55.2 million, or $0.61 per share, compared to $50.2 million, or $0.63 per share, for the same period in 2019.

Heron Therapeutics reported a net loss of $51.6 million, or $0.57 per share, for the three months ended March 31, 2020. Net product sales for the same period were $25.4 million. The company's cash, cash equivalents, and short-term investments totaled $356.3 million as of March 31, 2020, which is expected to fund operations into 2022.

Heron Therapeutics reported CINV franchise net product sales were $35.1 million, up 22% from the same period in 2018. Net loss for the quarter was $57.9 million, or $0.65 per share.